Beacon Pharma, a generic drugmaker from Bangladesh, will start clinical trials to see if the anti-viral drug Favipiravir is a safe option to treat Covid-19. In an interview to ET, Monjulrul Alam, Director, Beacon Pharma, said that the company is looking at the safety profile of the drug compared with HCQ that is being widely used by frontline workers handling Covid-19 patients. Favipiravir is an anti-viral drug of Japanese drug maker FujiFilm.